share_log

JMP Securities Maintains Market Outperform on Halozyme Therapeutics, Lowers Price Target to $71

JMP Securities Maintains Market Outperform on Halozyme Therapeutics, Lowers Price Target to $71

JMP證券維持Halozyme Therapeutics的市場跑贏大盤,將目標股價下調至71美元
Benzinga ·  05/08 13:58

JMP Securities analyst Jason Butler maintains Halozyme Therapeutics (NASDAQ:HALO) with a Market Outperform and lowers the price target from $72 to $71.

JMP Securities分析師傑森·巴特勒維持Halozyme Therapeutics(納斯達克股票代碼:HALO)的市場跑贏大盤,並將目標股價從72美元下調至71美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論